Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

  • 08/03/2018
  • Ad hoc Release

Bad Vilbel, March 8, 2018 – The Executive Board and Supervisory Board of STADA Arzneimittel AG (STADA) resolved today to propose to the General Meeting of STADA on June 6, 2018 the payment of a dividend in the amount of €0.11 per STADA share and to carry forward the remaining profits in the amount of €54m to new account. Thus, the dividend will be significantly lower than in previous years. In order to withstand the competition in the pharmaceuticals market, STADA must be able to invest in R&D, new products, technologies and markets. Therefore, the Executive Board and Supervisory Board consider it necessary to strengthen the company’s equity capital. The Executive Board expressly points out that the proposed appropriation of profits is subject to approval by the General Meeting.

As planned, STADA will today, on March 8, 2018 publish its annual financial statements as well as the consolidated annual financial statements for the 2017 financial year.

Contact
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]